18F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients

Anna R. Cervino, Fabio Pomerri, Rita Alfieri, Vanna C. Sileni, Carlo Castoro, Sara Galuppo, Laura Evangelista

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVES: The aim of the study was to evaluate the prognostic value of 18F-fluorodeoxyglucose PET/computed tomography (CT) after neoadjuvant therapy (NAT) in locally advanced esophageal cancer (EC) patients. MATERIALS AND METHODS: We recruited 79 EC patients from a sample of 210 who underwent 18F-fluorodeoxyglucose PET/CT after NAT and who did not have evidence or suspicion of distant metastases. All patients were followed up for a median period of 18 months (range: 2-53 months) from nuclear imaging. PET/CT findings were correlated with surgical management and long-term prognosis. The χ-test was used for categorical variables and the Student t-test for continuous data. Survival curves were computed using the Kaplan-Meier method. A P value less than 0.05 was considered statistically significant. RESULTS: Twenty patients (25.3%) had negative PET/CT and 59 (74.7%) had positive PET/CT results after NAT. Of the 20 patients with negative PET/CT results, eight underwent radical-intent surgery and 12 did not, whereas of the 59 patients with positive PET/CT 44 were scheduled for surgery and 15 were not (P

Original languageEnglish
Pages (from-to)160-168
Number of pages9
JournalNuclear Medicine Communications
Volume35
Issue number2
DOIs
Publication statusPublished - Feb 2014

Keywords

  • F-fluorodeoxyglucose PET/computed tomography
  • esophageal cancer
  • prognosis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of '<sup>18</sup>F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients'. Together they form a unique fingerprint.

Cite this